Ignite Creation Date:
2024-05-05 @ 5:00 PM
Last Modification Date:
2024-10-26 @ 9:26 AM
Study NCT ID:
NCT00362050
Status:
COMPLETED
Last Update Posted:
2007-08-29
First Post:
2006-08-08
Brief Title:
RBx11160 Phase II Dose Ranging Study RBxMMV05-06
Sponsor:
Medicines for Malaria Venture
Organization:
Medicines for Malaria Venture
Study Overview
Official Title:
A Phase II Double-Blind Parallel-Group Randomized Dose-Ranging Study Assessing the Antimalarial Activity and Safety of RBx 11160 Administered for 7 Days in Patients With Acute Uncomplicated Plasmodium Falciparum Malaria
Status:
COMPLETED
Status Verified Date:
2007-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The trial will identify the best dose of the synthetic peroxide RBx11160 to treat uncomplicated malaria Patients will be treated over 7 days with daily doses of 50 100 or 200 mg RBx11160
The study is designed to assess the antimalarial activity and safety of 3 dose levels of RBx 11160 administered once daily for 7 consecutive days The primary endpoint will be the time to 90 parasite clearance In future regulatory studies RBx 11160 is likely to be administered in combination with another antimalarial agent since the development plan follows the current recommendation of WHO for the treatment of uncomplicated malaria However it is critical to gather data on RBx 11160 when used as monotherapy in adult patients suffering from acute uncomplicated P falciparum malaria In malaria-endemic regions an adult population is defined on the basis of immune status rather than the legal age of consent Thus patients as young as 13 years of age can be enrolled provided consent has been obtained from a legal guardian in accordance with local practices and regulations This study will be conducted in compliance with International Conference on Harmonization ICH Good Clinical Practice GCP
The study is designed to assess the antimalarial activity and safety of 3 dose levels of RBx 11160 administered once daily for 7 consecutive days The primary endpoint will be the time to 90 parasite clearance In future regulatory studies RBx 11160 is likely to be administered in combination with another antimalarial agent since the development plan follows the current recommendation of WHO for the treatment of uncomplicated malaria However it is critical to gather data on RBx 11160 when used as monotherapy in adult patients suffering from acute uncomplicated P falciparum malaria In malaria-endemic regions an adult population is defined on the basis of immune status rather than the legal age of consent Thus patients as young as 13 years of age can be enrolled provided consent has been obtained from a legal guardian in accordance with local practices and regulations This study will be conducted in compliance with International Conference on Harmonization ICH Good Clinical Practice GCP
Detailed Description:
This is a Phase II double-blind multicenter randomized parallel-group dose-ranging study of the antimalarial activity and safety of 3 50 100 and 200 mg RBx 11160 dose levels administered as a single dose orally for 7 consecutive days in patients with acute uncomplicated P falciparum malaria mono-infection
At least 255 patients will be randomized at 4 study sites in South East Asia India and Africa Each investigational site will enroll between 60 and 90 patients to yield approximately 65 per protocol patients in each treatment arm Patients will be randomized to 1 of 3 dose groups Patients will be administered RBx 11160 with matching placebo tablets as required to maintain the study blind
The study is divided into 3 main periods including the Pre-Treatment Period ScreeningDay 0 the Treatment Period Days 0 through 6 Day 0 is the first day of study medication dosing and the Post-Treatment Period Day 14 - 1 day Day 21 - 1 day and Day 28 - 2 days
Patient participation will be for at least 28 2 days following the first dose of study medication Patients will be hospitalized for at least 4 days Days 0 1 2 and 3 but may remain in the hospital or live in the vicinity of the study site for the study duration If a patient is discharged from the hospital on Day 3 heshe will return to the study site or an authorized study staff member will visit the patient on Days 4 and 5 to administer study medication and perform indicated assessments The patient will return to the study site for study visits on Days 6 last dose of study medication administration 14 21 and 28
If adverse events reported during the study are unresolved by Day 28 patients will be followed for an additional 30 days or until resolution of the event or determination that no further medical management is deemed necessary Similarly the investigator will instruct the patient to return to the study site if any untoward event occurs within 30 days of completing study medication
At least 255 patients will be randomized at 4 study sites in South East Asia India and Africa Each investigational site will enroll between 60 and 90 patients to yield approximately 65 per protocol patients in each treatment arm Patients will be randomized to 1 of 3 dose groups Patients will be administered RBx 11160 with matching placebo tablets as required to maintain the study blind
The study is divided into 3 main periods including the Pre-Treatment Period ScreeningDay 0 the Treatment Period Days 0 through 6 Day 0 is the first day of study medication dosing and the Post-Treatment Period Day 14 - 1 day Day 21 - 1 day and Day 28 - 2 days
Patient participation will be for at least 28 2 days following the first dose of study medication Patients will be hospitalized for at least 4 days Days 0 1 2 and 3 but may remain in the hospital or live in the vicinity of the study site for the study duration If a patient is discharged from the hospital on Day 3 heshe will return to the study site or an authorized study staff member will visit the patient on Days 4 and 5 to administer study medication and perform indicated assessments The patient will return to the study site for study visits on Days 6 last dose of study medication administration 14 21 and 28
If adverse events reported during the study are unresolved by Day 28 patients will be followed for an additional 30 days or until resolution of the event or determination that no further medical management is deemed necessary Similarly the investigator will instruct the patient to return to the study site if any untoward event occurs within 30 days of completing study medication
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None